NASDAQ:ITOS iTeos Therapeutics (ITOS) Stock Price, News & Analysis $10.01 -0.01 (-0.10%) Closing price 04:00 PM EasternExtended Trading$9.98 -0.03 (-0.30%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About iTeos Therapeutics Stock (NASDAQ:ITOS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iTeos Therapeutics alerts:Sign Up Key Stats Today's Range$9.90▼$10.1850-Day Range$5.04▼$10.0652-Week Range$4.80▼$18.13Volume1.38 million shsAverage Volume647,333 shsMarket Capitalization$383.12 millionP/E RatioN/ADividend YieldN/APrice Target$15.86Consensus RatingHold Company OverviewiTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.Read More… iTeos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreITOS MarketRank™: iTeos Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 350th out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingiTeos Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageiTeos Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about iTeos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for iTeos Therapeutics are expected to decrease in the coming year, from ($3.49) to ($4.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iTeos Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of iTeos Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioiTeos Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about iTeos Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.57% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldiTeos Therapeutics does not currently pay a dividend.Dividend GrowthiTeos Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.57% of the float of iTeos Therapeutics has been sold short.Short Interest Ratio / Days to CoveriTeos Therapeutics has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in iTeos Therapeutics has recently increased by 8.30%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment0.24 News SentimentiTeos Therapeutics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for iTeos Therapeutics this week, compared to 3 articles on an average week.Search Interest7 people have searched for ITOS on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows1 people have added iTeos Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, iTeos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,396,703.00 in company stock.Percentage Held by Insiders12.50% of the stock of iTeos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.16% of the stock of iTeos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iTeos Therapeutics' insider trading history. Receive ITOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iTeos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Stock News HeadlinesiTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Bioventures 2018 L.P. Mpm Sells 630,191 SharesMay 16, 2025 | insidertrades.comResearch Analysts Offer Predictions for ITOS Q2 EarningsJune 2 at 1:19 AM | americanbankingnews.comWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Social Security — and his plan is set to roll out July 22. What's coming next isn't about trimming waste.June 2, 2025 | Altimetry (Ad)Wedbush Research Analysts Cut Earnings Estimates for ITOSMay 31 at 1:17 AM | americanbankingnews.comiTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder ValueMay 30 at 5:49 PM | nasdaq.comWells Fargo & Company Reiterates "Equal Weight" Rating for iTeos Therapeutics (NASDAQ:ITOS)May 30 at 3:09 AM | americanbankingnews.comiTeos Therapeutics (NASDAQ:ITOS) Downgraded by Wedbush to "Neutral"May 30 at 2:31 AM | americanbankingnews.comWedbush Downgrades iTeos Therapeutics (ITOS)May 29, 2025 | msn.comSee More Headlines ITOS Stock Analysis - Frequently Asked Questions How have ITOS shares performed this year? iTeos Therapeutics' stock was trading at $7.68 at the start of the year. Since then, ITOS stock has increased by 29.5% and is now trading at $9.9450. View the best growth stocks for 2025 here. How were iTeos Therapeutics' earnings last quarter? iTeos Therapeutics, Inc. (NASDAQ:ITOS) released its quarterly earnings results on Monday, April, 28th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. When did iTeos Therapeutics IPO? iTeos Therapeutics (ITOS) raised $151 million in an initial public offering on Friday, July 24th 2020. The company issued 8,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are iTeos Therapeutics' major shareholders? Top institutional investors of iTeos Therapeutics include RA Capital Management L.P. (9.53%), BVF Inc. IL (8.03%), 683 Capital Management LLC (4.57%) and Goldman Sachs Group Inc. (1.53%). Insiders that own company stock include Ansbert Gadicke, Bioventures 2018 LP Mpm, Boxer Capital, Llc, Matthew Gall and David Hallal. View institutional ownership trends. How do I buy shares of iTeos Therapeutics? Shares of ITOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iTeos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that iTeos Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings4/28/2025Today6/02/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITOS CIK1808865 Webwww.iteostherapeutics.com Phone339-217-0161FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$15.86 High Stock Price Target$46.00 Low Stock Price Target$8.00 Potential Upside/Downside+58.2%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$112.64 million Net MarginsN/A Pretax Margin-320.49% Return on Equity-20.11% Return on Assets-17.50% Debt Debt-to-Equity RatioN/A Current Ratio14.80 Quick Ratio14.80 Sales & Book Value Annual Sales$35 million Price / Sales10.96 Cash FlowN/A Price / Cash FlowN/A Book Value$16.08 per share Price / Book0.62Miscellaneous Outstanding Shares38,274,000Free Float31,967,000Market Cap$383.74 million OptionableOptionable Beta1.39 Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ITOS) was last updated on 6/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.